Sao Paulo's Butantan says vaccination output depends on ingredients from China
The Butantan biomedical center in Sao Paulo needs more active ingredients from China's Sinovac Biotech by the end of the month in order to hit targets for producing finished doses of a COVID-19 vaccine, the head of the institute said on Monday.
Butantan Director Dimas Covas told a news conference that the shipment from Sinovac was still waiting for export approval from the Chinese government.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- China
- Chinese
- Dimas Covas
- Sao Paulo
- Butantan
- Sinovac Biotech
Advertisement
ALSO READ
Cyber board says Chinese hack of US officials was 'preventable'
Indonesia's Prabowo pledges cooperation with Japan after promising China closer ties
US senator urges Biden to review alleged Nippon Steel ties to China
Scathing federal report rips Microsoft for shoddy security, insincerity in response to Chinese hack
With tears, a crowd of South Koreans bids farewell to beloved panda before her departure to China